Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

M. Chan; L. Haydu; A. M. Menzies; M. Azer; O. Klein; M. Lyle; A. Clements; A. Guminski; R. Kefford; G. Long

doi:10.1111/ajco.12106

Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

M. Chan, L. Haydu, A. M. Menzies, M. Azer, O. Klein, M. Lyle, A. Clements, A. Guminski, R. Kefford, G. Long

Research output: Contribution to journal › Meeting abstract

Original language	English
Pages (from-to)	42-42
Number of pages	1
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	9
Issue number	Supplement 2
DOIs	https://doi.org/10.1111/ajco.12106
Publication status	Published - Jul 2013
Externally published	Yes

Access to Document

10.1111/ajco.12106

Cite this

Chan, M., Haydu, L., Menzies, A. M., Azer, M., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R., & Long, G. (2013). Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD). Asia-Pacific Journal of Clinical Oncology, 9(Supplement 2), 42-42. https://doi.org/10.1111/ajco.12106

@article{26666f6552db40219cbdfa3eb0fd244a,

title = "Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)",

author = "M. Chan and L. Haydu and Menzies, {A. M.} and M. Azer and O. Klein and M. Lyle and A. Clements and A. Guminski and R. Kefford and G. Long",

year = "2013",

month = jul,

doi = "10.1111/ajco.12106",

language = "English",

volume = "9",

pages = "42--42",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "Wiley-Blackwell, Wiley",

number = "Supplement 2",

}

Chan, M, Haydu, L, Menzies, AM, Azer, M, Klein, O, Lyle, M, Clements, A, Guminski, A, Kefford, R & Long, G 2013, 'Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)', Asia-Pacific Journal of Clinical Oncology, vol. 9, no. Supplement 2, pp. 42-42. https://doi.org/10.1111/ajco.12106

Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD). / Chan, M.; Haydu, L.; Menzies, A. M. et al.
In: Asia-Pacific Journal of Clinical Oncology, Vol. 9, No. Supplement 2, 07.2013, p. 42-42.

Research output: Contribution to journal › Meeting abstract

TY - JOUR

T1 - Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

AU - Chan, M.

AU - Haydu, L.

AU - Menzies, A. M.

AU - Azer, M.

AU - Klein, O.

AU - Lyle, M.

AU - Clements, A.

AU - Guminski, A.

AU - Kefford, R.

AU - Long, G.

PY - 2013/7

Y1 - 2013/7

U2 - 10.1111/ajco.12106

DO - 10.1111/ajco.12106

M3 - Meeting abstract

C2 - 23809802

SN - 1743-7555

VL - 9

SP - 42

EP - 42

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

IS - Supplement 2

ER -